Kiniksa Pharmaceuticals International (KNSA) Projected to Announce Quarterly Earnings on Tuesday

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) is projected to release its Q3 2026 results before the market opens on Tuesday, October 27th. Analysts expect the company to announce earnings of $0.3710 per share and revenue of $260.66 million for the quarter. Individuals can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Tuesday, October 27, 2026 at 8:30 AM ET.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting the consensus estimate of $0.30. The business had revenue of $243.60 million during the quarter, compared to the consensus estimate of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.59% and a return on equity of 13.65%. On average, analysts expect Kiniksa Pharmaceuticals International to post $1.37 EPS for the current fiscal year and $2.07 EPS for the next fiscal year.

Kiniksa Pharmaceuticals International Price Performance

Shares of Kiniksa Pharmaceuticals International stock opened at $76.73 on Monday. Kiniksa Pharmaceuticals International has a twelve month low of $35.20 and a twelve month high of $84.06. The business has a 50-day moving average price of $78.13 and a 200-day moving average price of $65.18. The firm has a market cap of $5.99 billion, a price-to-earnings ratio of 79.10 and a beta of 0.04.

Analysts Set New Price Targets

KNSA has been the subject of a number of research reports. Zacks Research lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 30th. Weiss Ratings upgraded Kiniksa Pharmaceuticals International from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. JPMorgan Chase & Co. lifted their price objective on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Wall Street Zen cut Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. Finally, Wells Fargo & Company started coverage on Kiniksa Pharmaceuticals International in a report on Wednesday, September 30th. They set an “overweight” rating and a $87.00 price objective on the stock. Eight research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $93.14.

Insider Activity

In other Kiniksa Pharmaceuticals International news, Director G. Bradley Cole sold 3,673 shares of the company’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total transaction of $299,092.39. Following the sale, the director directly owned 11,672 shares in the company, valued at $950,450.96. This represents a 23.94% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Michael R. Megna sold 4,600 shares of the company’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $80.30, for a total value of $369,380.00. Following the sale, the chief accounting officer owned 29,062 shares in the company, valued at approximately $2,333,678.60. This trade represents a 13.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 51.98% of the company’s stock.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for patients with serious and often under-treated immunological diseases. The company’s research and development efforts are centered on targeting specific pathways involved in inflammation and immune-system dysfunction.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor. In the United States, ARCALYST is approved for reducing the risk of recurrence in patients with recurrent pericarditis and for the treatment of cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome, in eligible patients.

The company also maintains a pipeline of investigational medicines designed to address autoimmune and inflammatory conditions.